# Phase 2 nephritis trials recruiting: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials in phase 2 for nephritis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 nephritis trials: 22 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/nephritis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07937501 | A Study of IPG11406 Tablets in Participants With Lupus Nephritis | Nanjing Immunophage Biotech Co., Ltd | Phase 2 | Not yet recruiting | Lupus Nephritis | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937501) |
| July 28, 2026 | NCT07729826 | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to... | AbelZeta Inc. | Phase 2 | Not yet recruiting | Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729826) |
| July 23, 2026 | NCT07721363 | Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial | Assistance Publique - Hôpitaux de Paris | Phase 2 | Not yet recruiting | Lupus Nephritis, Membranous Nephropathy | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721363) |
| May 20, 2026 | NCT07598396 | A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | Hoffmann-La Roche | Phase 2 | Recruiting | Lupus, Systemic Lupus Erythematosus, Lupus Nephritis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598396) |
| May 6, 2026 | NCT07570862 | A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis | Fate Therapeutics | Phase 2 | Recruiting | Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III... | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570862) |
| April 21, 2026 | NCT07541287 | A Study of JADE101 in Participants With Immunoglobulin A Nephropathy | Jade Biosciences, Inc. | Phase 2 | Recruiting | IgA Nephropathy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541287) |
| April 13, 2026 | NCT07523581 | EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety | Eloxx Pharmaceuticals, Inc. | Phase 2 | Recruiting | Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523581) |
| February 6, 2026 | NCT07393451 | A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis | Simcere Pharmaceutical Co., Ltd | Phase 2 | Not yet recruiting | Lupus Nephritis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07393451) |
| January 23, 2026 | NCT07363460 | Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | Lupus Nephritis (LN) | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07363460) |
| January 14, 2026 | NCT07340463 | The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months... | Nanjing University School of Medicine | Phase 2 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07340463) |
| January 9, 2026 | NCT07328581 | A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis | iCell Gene Therapeutics | Phase 2 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328581) |
| July 8, 2025 | NCT07053800 | Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) | Autolus Limited | Phase 2 | Recruiting | Lupus Nephritis | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07053800) |
| June 26, 2025 | NCT07038382 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab... | Shanghai Henlius Biotech | Phase 2 | Recruiting | Membranous Nephropathy, Lupus Nephritis (LN) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07038382) |
| May 21, 2025 | NCT06983028 | Atacicept in Multiple Glomerular Diseases | Vera Therapeutics, Inc. | Phase 2 | Recruiting | pMN, IgAN, Nephrotic Syndrome, MCD, FSGS | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06983028) |
| May 17, 2024 | NCT06419205 | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G | Akebia Therapeutics | Phase 2 | Recruiting | IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06419205) |
| December 4, 2023 | NCT06155604 | SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease | The University of Hong Kong | Phase 2 | Recruiting | Lupus Nephritis, Chronic Kidney Diseases | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06155604) |
| September 28, 2023 | NCT06058078 | RY\_SW01 Cell Injection Therapy in Active Lupus Nephritis | Jiangsu Renocell Biotech Company | Phase 2 | Recruiting | Lupus Nephritis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06058078) |
| September 13, 2022 | NCT05538208 | The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study | Children's Hospital Medical Center, Cincinnati | Phase 2 | Recruiting | Lupus Nephritis | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05538208) |
| January 21, 2022 | NCT05201469 | VIBRANT: VIB4920 for Active Lupus Nephritis | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Recruiting | Lupus Nephritis | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05201469) |
| September 9, 2021 | NCT05039619 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis... | Hoffmann-La Roche | Phase 2 | Recruiting | Lupus Nephritis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05039619) |
| August 13, 2021 | NCT05003986 | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | Travere Therapeutics, Inc. | Phase 2 | Recruiting | Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05003986) |
| September 17, 2018 | NCT03673748 | Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells | Red de Terapia Celular | Phase 2 | Recruiting | Lupus Nephritis, Lupus Erythematosus | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03673748) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| Jiangsu Renocell Biotech Company | 1 |
| Autolus Limited | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| AbelZeta Inc. | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| [Shanghai Henlius Biotech](https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech) | 1 |
| Travere Therapeutics, Inc. | 1 |
| The University of Hong Kong | 1 |
| Simcere Pharmaceutical Co., Ltd | 1 |
| [Akebia Therapeutics](https://specstream.ai/data/clinical-trials/company/akebia-therapeutics) | 1 |
| Nanjing Immunophage Biotech Co., Ltd | 1 |
| Vera Therapeutics, Inc. | 1 |
| Jade Biosciences, Inc. | 1 |
| iCell Gene Therapeutics | 1 |
| Eloxx Pharmaceuticals, Inc. | 1 |
| Red de Terapia Celular | 1 |
| Nanjing University School of Medicine | 1 |
| [Fate Therapeutics](https://specstream.ai/data/clinical-trials/company/fate-therapeutics) | 1 |
| [Haisco Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/haisco-pharmaceutical-group-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 11 |
| China | 6 |
| Brazil | 4 |
| United Kingdom | 4 |
| Italy | 3 |
| Spain | 3 |
| France | 2 |
| Poland | 2 |
| Mexico | 2 |
| South Africa | 2 |
| Greece | 1 |
| Vietnam | 1 |
| Germany | 1 |
| Netherlands | 1 |
| Sweden | 1 |
| Canada | 1 |
| Peru | 1 |
| Russia | 1 |
| Hong Kong | 1 |
| Argentina | 1 |
| Colombia | 1 |
| Australia | 1 |
| New Zealand | 1 |
| South Korea | 1 |
| Taiwan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Laser cutting companies in the United States](https://specstream.ai/data/businesses/laser-cutting-companies/united-states)
- [Patent law firms in the United States](https://specstream.ai/data/businesses/patent-law-firms/united-states)
- [Sandblasting companies in the United States](https://specstream.ai/data/businesses/sandblasting-companies/united-states)
- [Ultrasound imaging clinics in the United States](https://specstream.ai/data/businesses/ultrasound-imaging-clinics/united-states)
- [B2B advertising and marketing companies in the United States](https://specstream.ai/data/businesses/b2b-advertising-and-marketing-companies/united-states)
- [Certification bodies in the United States](https://specstream.ai/data/businesses/certification-bodies/united-states)
